Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Praxbind
Sort By
Newest First
1 / 1
1 / 1
Drug Development
Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide
Boehringer Ingelheim
PR-M05-18-NI-034
May 09, 2018
